MOLN Stock Analysis: Buy, Sell, or Hold?
MOLN - Molecular Partners AG American Depositary Shares
$4.38
-0.02 (-0.45%)
▼
5d:
+2.1%
30d:
+6.83%
90d:
+8.41%
WAIT
LOW Confidence
Analysis Updated: Aug 25, 2026 12:00 AM ET
Earnings: Aug 24, 2026
0d
Get Alerted When MOLN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: MOLN shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: MOLN shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: MOLN is currently trading at $4.38, which is considered extended relative to its 30-day fair value range of $3.96 to $4.30. From a valuation perspective, the stock is trading at a discount (Forward PE: -20.9) compared to its historical average (31.9). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, MOLN is in a downtrend. The price is approaching resistance at $4.40. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: MOLN scores 13/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.19 (+155.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MOLN is in a downtrend. The price is approaching resistance at $4.40. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: MOLN scores 13/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.19 (+155.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$3.96 -
$4.30
Company Quality Score
31/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
33.3%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (13/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 155.6% below Wall St target ($11.19)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 31/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.96 -
$4.30
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$4.11
Resistance Level
$4.40
Current Trend
Downtrend
Technical data as of
Aug 25, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-20.92
Wall Street Target
$11.19
(+155.6%)
Revenue Growth (YoY)
-100.0%
PE vs Historical
-20.9 vs 31.9
CHEAP
Share & Embed Analysis
Last updated: August 25, 2026 8:54 PM ET
Data refreshes hourly during market hours. Next update: 9:54 PM
Data refreshes hourly during market hours. Next update: 9:54 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MOLN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 37 SELL |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 54 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$108 | 56 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 43 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$138 | 70 BUY |
